Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 19, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific share transaction details within an employee retirement plan.
Material Changes
The filing details changes in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan"):
- December 14, 2006: Holdings decreased from 17,363,921 to 17,315,128 ADRs at an average price of $52.55.
- December 15, 2006: Holdings increased from 17,315,128 to 17,349,366 ADRs at an average price of $52.76.
These movements were driven by fund activity rather than direct trading by the directors.
Management Commentary and Risks
The Plan is a discretionary fund where all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Two directors, Dr. J P Garnier and Dr. M M Slaoui, are noted as potentially interested in the shares held in the fund in the same capacity as other employees. The notification complies with Disclosure Rule 3.1.4R(1)(b). No other risks, contingencies, or unusual items are discussed in this filing.
Investor Verification Points
- Confirm the total aggregate holdings of the US Retirement Savings Plan to assess the scale of potential director interest.
- Verify if similar transactions occurred in other periods to identify patterns in fund management.
- Review the full 20-F annual report for comprehensive financial performance data, as this 6-K contains no financial statements.